FA
CTMX icon

Forefront Analytics’s CytomX Therapeutics CTMX Stock Holding History

Forefront Analytics’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.9K Buy
25,033
+12,557
+101% +$47.9K 0.1% 34
2026
Q1 		$58.6K Sell
12,476
-6,223
-33% -$31.6K 0.05% 38
2025
Q4 		$79.7K Buy
18,699
+590
+3% +$2.24K 0.07% 39
2025
Q3 		$57.8K Sell
18,109
-9,589
-35% -$21.6K 0.06% 43
2025
Q2 		$62.9K Sell
27,698
-72,372
-72% -$117K 0.07% 40
2025
Q1 		$63.1K Buy
100,070
+35,811
+56% +$27.8K 0.07% 43
2024
Q4 		$66.2K Buy
64,259
+4,499
+8% +$4.84K 0.03% 64
2024
Q3 		$70.5K Sell
59,760
-4,305
-7% -$5.47K 0.03% 66
2024
Q2 		$78.2K Buy
64,065
+43,176
+207% +$85.9K 0.04% 67
2024
Q1 		$45.5K Sell
20,889
-9,957
-32% -$18.4K 0.02% 67
2023
Q4 		$47.8K Sell
30,846
-18,575
-38% -$24.4K 0.02% 67
2023
Q3 		$63.8K Sell
49,421
-175
-0.4% -$276 0.04% 61
2023
Q2 		$85.3K Buy
49,596
+23,184
+88% +$38.5K 0.05% 59
2023
Q1 		$39.9K Buy
26,412
+1,625
+7% +$3.67K 0.02% 77
2022
Q4 		$39.7K Sell
24,787
-23,082
-48% -$34.1K 0.02% 71
2022
Q3 		$71K Buy
47,869
+11,950
+33% +$18.4K 0.04% 57
2022
Q2 		$67K Buy
35,919
+21,275
+145% +$40.7K 0.03% 58
2022
Q1 		$40K Buy
14,644
+900
+7% +$3.46K 0.01% 68
2021
Q4 		$62K Buy
13,744
+350
+3% +$2.05K 0.02% 61
2021
Q3 		$68K Buy
+13,394
New +$71.7K 0.02% 63

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Forefront Analytics's CTMX Position: Q2 2026 in Review

Forefront Analytics increased its CytomX Therapeutics (CTMX) stake by 101% in Q2 2026, buying an estimated $47.9K and bringing the position to 25,033 shares worth $93.9K. The position accounts for 0.1% of the portfolio, ranked #34.

Forefront Analytics first reported a position in CTMX in Q3 2021 and has held it in 20 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Forefront Analytics held 25,033 shares of CytomX Therapeutics worth $93.9K as of Q2 2026.
  • Forefront Analytics bought 12,557 CytomX Therapeutics shares in Q2 2026, an estimated $47.9K.
  • CytomX Therapeutics made up 0.1% of Forefront Analytics's portfolio in Q2 2026, its #34 holding.
  • Forefront Analytics first reported a position in CytomX Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Forefront Analytics's 13F filing for Q2 2026, filed 13 Aug 2026.